Form 4: Supernus CEO Sells Shares Under 10b5-1 Plan

Supernus Pharmaceuticals CEO Jack Khattar reported the sale of 35,000 shares of common stock from a trust under a pre-arranged 10b5-1 trading plan.

Summary

• Jack A. Khattar, President, CEO, and Director of Supernus Pharmaceuticals, Inc. (SUPN), reported transactions involving the company's common stock.
• On March 13, 2026, 12,500 shares were transferred from the KBT Trust to Mr. Khattar directly without consideration, increasing his direct ownership.
• Also on March 13, 2026, a total of 35,000 shares were sold from the KBT Trust under a Rule 10b5-1 trading plan adopted on December 12, 2025.
• The sales included 24,138 shares at a weighted average price of $50.09, 10,742 shares at a weighted average price of $51.00, and 120 shares at $51.75.
• Following these transactions, Mr. Khattar directly owns 1,241,144 shares and indirectly owns 958,100 shares through the KBT Trust, totaling 2,199,244 shares beneficially owned.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral event. While insider selling can sometimes be a negative signal, the pre-arranged 10b5-1 plan mitigates concerns about opportunistic trading, suggesting a planned portfolio adjustment rather than a reaction to adverse company news.

Positives

• The sales were conducted under a pre-arranged 10b5-1 trading plan, indicating a planned divestment rather than an immediate reaction to new, undisclosed information.

Negatives

• Insider selling, even under a 10b5-1 plan, can sometimes be perceived negatively by the market as it reduces the insider's direct stake in the company.
• A total of 35,000 shares were sold from the KBT Trust, representing a reduction in indirect beneficial ownership.

Risks

• Potential for negative market perception due to insider selling, despite the pre-planned nature of the transactions.

Future Outlook

The filing does not contain any forward-looking statements or guidance.

Industry Context

StockSavvy.ai notes that insider selling under a 10b5-1 plan is a common practice for executives to diversify holdings and manage liquidity without implying a negative outlook on the company's future. Such plans are pre-arranged to avoid accusations of trading on material non-public information.

Stakeholder Impact

• Shareholders: May interpret the insider sale as a slight negative, though the 10b5-1 plan context should temper concerns about the company's prospects.

Key Dates

Recommendation

The insider sale by CEO Jack Khattar, while reducing his indirect holdings, was conducted under a pre-established 10b5-1 trading plan. This suggests a planned portfolio diversification rather than a reaction to new negative information about Supernus Pharmaceuticals. Given the context, this transaction alone does not provide a strong signal for a change in investment thesis, warranting a 'hold' recommendation.

Keywords

Supernus Pharmaceuticals, SUPN, Insider Trading, Form 4, Jack Khattar, Stock Sale, 10b5-1 Plan, CEO, Director